ModifiedCignaPolicy N/A

Oncology (Oral - Immunomodulator) - Lenalidomide Prior Authorization Policy

Defines prior authorization requirements and medical necessity criteria for lenalidomide (Revlimid and generic) for oncology and related hematologic indications under Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyOncology (Oral - Immunomodulator) - Lenalidomide Prior Authorization Policy

Policy CodePolicy N/A

Change TypeMaterial revisions to prior-treatment requirements and Hodgkin lymphoma criteria

Effective DateN/A

Next Review DateMay 14, 2025

Key ActionSubmit prior authorization requests with supporting clinical information per plan terms; ensure documented prior regimens or combination therapy as required for the indication.

SourceLink

POLICY UPDATE CHANGES

Criterion has been updated to state patient has tried at least 'three' other regimens, as per guidelines (previously it said one other regimen).

Policy name was changed from 'Oncology - Lenalidomide PA Policy' to 'Oncology (Oral - Immunomodulator) - Lenalidomide PA Policy'.

Examples of chemotherapy regimens (ICE, DHA + platinum, dose-adjusted EPOCH, HyperCVAD, IVAC) were added as a Note for regimen examples.

ESHAP was removed from the list of examples in the Note.

The requirement that a Hodgkin Lymphoma patient has tried at least three other regimens with examples was removed; instead a requirement about relapsed/refractory disease and not being a candidate for high-dose therapy/autologous stem cell rescue was added.

1 yeartypical approval duration

Multiple indicationsdisease areas listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medical Necessity and Coverage Criteria

Indication-specific medical necessity criteria

Covered when ALL of the following are met for the specified indication (approval generally for 1 year):

General requirement: Patient is ≥ 18 years of age when specified in indication-specific criteria.

Indication-specific pathways

Follicular lymphoma: Patient ≥ 18 AND one of: medication used in combination with rituximab OR medication used in combination with Gazyva (obinutuzumab) OR patient has tried at least one other regimen.
Mantle cell lymphoma: Patient ≥ 18 AND one of: medication used in combination with rituximab OR patient has tried at least one other regimen.
Marginal zone lymphoma: Patient ≥ 18 AND one of: medication used in combination with rituximab OR patient has tried at least one other regimen.
Multiple myeloma: Patient ≥ 18.
Approval for 1 year.
Myelodysplastic syndrome (MDS): Patient ≥ 18 AND one of: symptomatic anemia OR transfusion-dependent anemia OR anemia not controlled with an erythropoiesis-stimulating agent OR all of: MDS/MPN overlap neoplasm AND SF3B1 mutation AND thrombocytosis.
Other B-cell lymphomas (including DLBCL and others): Patient ≥ 18 AND patient has tried at least one other regimen.
Castleman disease: Relapsed/refractory or progressive disease.
Chronic lymphocytic leukemia (CLL): Patient ≥ 18 AND relapsed/refractory disease AND tried at least one Bruton tyrosine-kinase inhibitor AND tried at least one BCL2 inhibitor.
Histiocytic neoplasms: Patient ≥ 18 AND either: Langerhans cell histiocytosis with single-system multifocal skin disease OR relapsed/refractory disease OR Rosai‑Dorfman disease.
Hodgkin lymphoma (classic): Patient ≥ 18 AND relapsed/refractory disease AND prescriber states patient is not a candidate for high‑dose therapy and autologous stem cell rescue.
Kaposi sarcoma: Relapsed/refractory disease AND patient has tried at least one other medication.
Myelofibrosis: Patient ≥ 18 AND prescriber states patient has anemia with presence of del(5q) AND lenalidomide is used in combination with prednisone.
Primary CNS lymphoma: Relapsed/refractory disease OR patient not a candidate for high‑dose methotrexate OR intolerance to high‑dose methotrexate.
POEMS syndrome: Patient ≥ 18 AND lenalidomide used in combination with dexamethasone.
Small lymphocytic leukemia: Patient ≥ 18 AND relapsed/refractory disease AND tried at least one Bruton tyrosine-kinase inhibitor AND tried at least one BCL2 inhibitor.
Systemic light chain amyloidosis: Patient ≥ 18 AND lenalidomide used in combination with dexamethasone.
T-cell lymphoma: Patient ≥ 18 AND either: peripheral T‑cell lymphoma OR (T‑cell leukemia/lymphoma AND tried at least one other regimen) OR (hepatosplenic T‑cell lymphoma AND tried at least two other regimens).

ref

title

Lenalidomide is not medically necessary for any indications or uses that are not explicitly listed in this policy. The policy exclusions will be updated as new published data become available.

Revlimid (lenalidomide capsules) is considered not medically necessary for any use(s) not specified within this policy.

Any use of lenalidomide that is not specifically described and justified by the coverage criteria in this policy is considered not medically necessary and may be denied.

All other uses of Revlimid (lenalidomide) beyond the oncology and related hematologic conditions listed with approval criteria in this policy are considered not medically necessary.

Covered Products and Codes

Covered productsNDC | mixedCovered

Revlimid (lenalidomide capsules)

Drug product referenced (brand and generic)

Prior Authorization, Documentation, and Billing Guidance

Denial Risk

Coding / benefit mismatch

Claims submitted for services that are not accompanied by covered diagnosis or procedure codes under the applicable coverage policy will be denied as not covered. When billing, providers must use the most appropriate codes as of the effective date of the submission. In the event of a conflict between this coverage policy and a customer's specific benefit plan document, the benefit plan document supersedes the coverage policy. Providers should submit requests in accordance with the applicable benefit plan terms and include supporting clinical information; medical directors may exercise clinical judgment when making individual coverage determinations.

Claims without covered diagnosis or procedure codes will be denied as not covered.
Use the most appropriate codes as of the submission effective date.
Follow the applicable benefit plan document — it supersedes this policy when in conflict.
Include supporting clinical information with prior authorization requests; medical directors have discretion.

Clinical Background

Lenalidomide is a thalidomide analog used as monotherapy and in combination regimens across multiple hematologic malignancies and related disorders (for example, various lymphomas, multiple myeloma, and myelodysplastic syndromes). National Comprehensive Cancer Network (NCCN) guidelines incorporate lenalidomide for many of these indications with varying recommendation categories. This policy defines the specific indication-based criteria under which lenalidomide (Revlimid and generics) is considered medically necessary; uses not listed are considered not medically necessary.

Drug and Term Definitions

Lenalidomide — definition and indications summary

DrugLenalidomide (Revlimid) — a thalidomide analog used in adults for multiple hematologic malignancies and related disorders.

Key FDA‑listed indicationsFollicular lymphoma (previously treated) in combination with rituximab; Mantle cell lymphoma (relapsed/progressed after two prior therapies, one including bortezomib); Marginal zone lymphoma (previously treated) in combination with rituximab; Multiple myeloma (maintenance post‑autologous HSCT and treatment with dexamethasone); Myelodysplastic syndrome (transfusion‑dependent anemia due to del(5q)).

Typical approval durationApprovals are generally provided for 1 year for covered indications.

Common combinationsUsed in combination with rituximab or obinutuzumab for certain lymphomas; with dexamethasone for multiple myeloma and POEMS; with prednisone for myelofibrosis when indicated.

Regulatory note for MDSIndicated for transfusion‑dependent anemia due to low‑ or intermediate‑1‑risk MDS associated with a deletion 5q abnormality (with or without other cytogenetic abnormalities).

First-line, Second-line, and Salvage Therapy Definitions

first-line | second-line | salvage

Line of therapy per NCCN mentions: Lenalidomide is used across first-line (for certain follicular indications in combination with rituximab), second-line, and subsequent therapy settings depending on lymphoma subtype and regimen.

first-line | second-line | salvage (alternate/location)

Varied line-of-therapy requirements: Policy includes line-of-therapy specific requirements across multiple conditions (e.g., initial versus relapsed/refractory language; some indications allow initial palliative use).

Molecular and Cytogenetic Criteria

SF3B1 biomarker requirement

BiomarkerSF3B1 mutation

Required contextRequired for an option for approval in a myelodysplastic syndrome/myeloproliferative neoplasm overlap neoplasm when accompanied by thrombocytosis.

Associated criteriaPart of the MDS/MPN overlap pathway: patient must have SF3B1 mutation plus thrombocytosis and meet age requirement (≥18).

Source guidanceAdded as an option for approval in the policy history to permit use in MDS/MPN overlap with SF3B1 mutation and thrombocytosis.

del(5q) biomarker requirement

Biomarkerdel(5q)

Examples of Required or Preceding Regimens

Example regimen
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
CVP (cyclophosphamide, vincristine, prednisone)
Bendamustine + rituximab
RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
HyperCVAD + rituximab (alternating with high‑dose methotrexate and cytarabine)
EPOCH + rituximab (including dose‑adjusted EPOCH examples)
ICE (ifosfamide, carboplatin, etoposide) ± rituximab
DHA (dexamethasone, cytarabine) + platinum (carboplatin, cisplatin, or oxaliplatin)
RDHA + platinum (rituximab, dexamethasone, cytarabine) + platinum
Targeted agents (e.g., BTK inhibitors such as ibrutinib, acalabrutinib, zanubrutinib; BCL2 inhibitors)

Specific regimen example
ICE (ifosfamide, carboplatin, etoposide)
DHA + platinum (dexamethasone and cytarabine plus carboplatin, cisplatin, or oxaliplatin)
Dose‑adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) ± rituximab
HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating with high‑dose methotrexate and cytarabine
IVAC (ifosfamide, etoposide, cytarabine)